A proactive , multifactorial intervention strategy incorporating single-pill amlodipine/atorvastatin ( SPAA ) ( 5-10/10 mg up-titrated to 5-10/20 mg , where approved ) is more effective than physician 's usual care ( UC ) for reducing calculated 10 year coronary heart disease ( CHD ) risk , in patients with hypertension and additional risk factors ( CRUCIAL trial : Curr Med Res Opin 2011 ; 27:821 -- 33 ) .
